Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL201 in mCRPC
NCT06241846Phase 2Recruiting
- Sponsor
- MediLink Therapeutics
- Start
- Feb 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label trial of YL201 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by MediLink Therapeutics. Primary endpoints: Objective Response Rate at 36 months, Radiographic Progression Free Survival at 36 months and 1 more. Started Feb 2024; status: recruiting.
02
Drugs
YL201
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06241846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06241846.